Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results
February 22, 2017 5:52 AM ESTMizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company reported 2016 fourth quarter revenues and EPS figures above consensus.
Koffler comments, "4Q:16 beat was great but not surprising since consensus largely omitted a $15M milestone associated with regulatory approval in Japan: IRWD reported 4Q:16 revenues of $87.5M... More
Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
February 21, 2017 4:03 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.12 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.46 million versus the consensus estimate of $77.34 million.
2017 Financial Guidance
Ironwood expects 2017 R&D expenses to be in the range of $145... More